Veradermics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Recent price momentum is +13.5% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 8.1% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 124.39
- Open
- 121.98
- Day range
- 118.99 - 124.00
- Avg price
- 120.43
- Volume
- 375.00K
- Turnover
- 45.16M
- Turnover ratei
- 1.16%
- Volume ratioi
- 0.78
- Amplitudei
- 4.03%
- 52-week rangei
- 32.00 - 156.63
Valuation
- P/Ei
- -53.52
- P/E (TTM)i
- -49.08
- P/Bi
- 6.33
- EPSi
- -2.23
- Book value / shi
- 18.88
- Net profit
- -94.22M
- Net assets
- 796.48M
Share structure
- Market cap
- 5.04B
- Float capi
- 3.86B
- Shares out
- 42.20M
- Float sharesi
- 32.25M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-02-04
23.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+41.08M net over the window
Short interest
- Shares short
- 3.39M
- % of floati
- 8.11%
- Days to coveri
- 5.06
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Veradermics (MANE)?
Veradermics last traded at 119.52. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Veradermics's market cap?
About 5.04B.
What is the P/E ratio of Veradermics?
The trailing twelve-month P/E is -49.08. The Valuation tab shows it against the stock's own five-year range.
Does Veradermics pay a dividend?
Veradermics does not currently pay a regular dividend.
Is Veradermics a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 180.67, which implies 51.2% upside from the current price. This is not investment advice.
What is Veradermics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Veradermics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
Veradermics discussion 0 comments